Clinical Trial

Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 1, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to compare the efficacy of intralesional triamcinolone and verapamil in patients presenting with keloid at our local setting. The results will guide us towards better management of keloids by choosing the more appropriate treatment. Adequate treatment will reduce significant emotional and physical distress in patients. We hypothesized that mean reduction in Vancouver Scar Score is higher in triamcinolone acetonide group compared to verapamil after three months of treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-20.
Trial Details
NCT Number NCT06897969
Lead Sponsor Nishtar Medical University
Conditions Keloid Scars
Enrollment 60 participants
Start Date 2025-04-01
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-01